{
    "organizations": [],
    "uuid": "0a0d583dfeabd6dca6c5cde3d333cab807a1ac88",
    "author": "",
    "url": "https://www.reuters.com/article/brief-united-therapeutics-says-fda-accep/brief-united-therapeutics-says-fda-accepted-to-review-its-nda-for-implantable-system-for-remodulin-idUSFWN1RC020",
    "ord_in_thread": 0,
    "title": "BRIEF-United Therapeutics Says FDA Accepted To Review Its NDA For Implantable System For Remodulin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 30 (Reuters) - United Therapeutics Corp:\n* UNITED THERAPEUTICS- NOTIFIED BY FDA CO'S NDA FOR IMPLANTABLE SYSTEM FOR REMODULIN ACCEPTED FOR 6-MONTH REVIEW AS CLASS 2 RESUBMISSION - SEC FILING Source text: ( bit.ly/2E6Hb6r ) Further company coverage:\n ",
    "published": "2018-03-30T23:48:00.000+03:00",
    "crawled": "2018-03-31T00:03:37.016+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "united",
        "therapeutic",
        "corp",
        "united",
        "notified",
        "fda",
        "co",
        "nda",
        "implantable",
        "system",
        "remodulin",
        "accepted",
        "review",
        "class",
        "resubmission",
        "sec",
        "filing",
        "source",
        "text",
        "company",
        "coverage"
    ]
}